Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Import Law Likely In ‘04, AARP’s Rother Says; FDA Thinks States Will Wait

Executive Summary

Congress will pass prescription drug importation legislation in 2004 as a "bridge" to the Medicare drug benefit in 2006, AARP Policy & Strategy Director John Rother predicted during a Kaiser Family Foundation webcast Dec. 2

You may also be interested in...



Reimportation Should Await Track/Trace Technology, HIGPA White Paper Says

Providers interested in acquiring pharmaceuticals from outside the U.S. should first concentrate on advocacy for stronger anti-counterfeiting protections, the Health Industry Group Purchasing Association recommends in a product sourcing "white paper.

Reimportation Should Await Track/Trace Technology, HIGPA White Paper Says

Providers interested in acquiring pharmaceuticals from outside the U.S. should first concentrate on advocacy for stronger anti-counterfeiting protections, the Health Industry Group Purchasing Association recommends in a product sourcing "white paper.

FDA “Credibility,” “Authority” Threatened By State Imports, PhRMA Says

FDA needs to take action against state and local governments that encourage drug importation, Pharmaceutical Research & Manufacturers of America Assistant General Counsel Scott Lassman told a Food & Drug Law Institute audioconference Dec. 16

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel